Interesting point PHE that "3TC also comes off patent in 2011"....

Interesting point PHE that "3TC also comes off patent in 2011". AVX will now have to prove beyond doubt that ATC is worth paying a premium for, once 3TC comes off patent and cheaper generic products flood the market.

Also noted JC's comment about allowing large pharma to dictate terms, because that is precisely what Tibotec managed to do to us for 10 months with no valid outcome. As I have said previously, all will be forgiven if we can reach the holy grail of partnership and true shareholder value that we so often read about in every Chairman's/CEO address. However, the longer it hovers at these ridiculous valuations, the more I hear barking.